ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VERA vs SDGR // EV/EBITDA & P/E VALUATION

Vera Therapeutics Inc. (Class A) (NASDAQ) VS. Schrodinger Inc. (NASDAQ) • 15-METRIC TALLY: VERA 0 — SDGR 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VERA VS. SDGR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VERA SDGR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 55.70% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -10.99% 0.56% -11.55 SDGR /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -40.40% — TIE /net-margins <GO>
Revenue Growth (YoY) — 23.30% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 2.64 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 7/9 -5.00 SDGR /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.8 53.0 -0.15 SDGR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.20B $2.24B -$43.3M SDGR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VERA REV SDGR REV VERA GROSS % SDGR GROSS % VERA FCF SDGR FCF
FY 2025 $0 $255.9M — 55.7% -$241.7M $12.5M
FY 2024 $0 $207.5M — 63.6% -$135.7M -$164.7M
FY 2023 $0 $216.7M — — -$92.2M -$136.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VERA // BETA —
SDGR // BETA —